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Abstract
Background: Hemodynamic instability is one of the leading causes of intensive care unit (ICU) admission. Early
stabilization of hemodynamics is associated with improved outcome. The monitoring used to guide hemodynamic
support may influence the time needed to achieve stable hemodynamics. Visualization of the heart using
echocardiography offers the advantage of direct measurement of cardiac volumes and ventricular function.
A miniaturized monoplane transesophageal echocardiography (TEE) probe was developed, allowing for almost
continuous qualitative hemodynamic TEE assessment (hTEE) after brief bedside training. The primary objective of
the study is to assess whether hemodynamic monitoring using the hTEE technology shortens time to resolution
of shock in ICU patients in comparison to standard monitoring using a central venous catheter, pulmonary artery
catheter, or conventional echocardiography.
Methods: Five hundred consecutive subjects with circulatory shock (low mean arterial blood pressure (MAP) and
signs of organ hypoperfusion) at the time of ICU admission are included in the study. The subjects are randomly
assigned to one of four groups using a 2 × 2 factorial design stratified by method of hemodynamic monitoring
(hTEE vs standard hemodynamic monitoring) and frequency of hemodynamic assessments (minimum every 4 h
vs standard of care). The primary study outcome is the time from study inclusion to resolution of circulatory shock,
defined as MAP > 60 mmHg for ≥ 4 h after discontinuation of vasopressors and inotropes. The hTEE monitoring
consists of the acquisition of three defined echocardiography views: Transgastric mid-esophageal short axis with
measurement of fractional area change of left ventricle, mid-esophageal four-chamber view with measurement of
the ratio of right to left ventricular area, and mid-esophageal ascending aortic short-axis view with measurement
of the superior vena cava collapsibility index. In the control groups, monitoring modalities, including conventional
TTE and TEE but not hTEE, are at the discretion of the treating physician. The interpretation of hemodynamic
monitoring and the subsequent changes in patient management are recorded after each hemodynamic assessment.
Differences in the primary and further secondary time-to-event outcomes will be assessed using a competing risk
model accounting for the competing risk of death.
(Continued on next page)
* Correspondence: tobias.merz@insel.ch
1Department of Intensive Care Medicine, University Hospital, and University
of Bern, 3010 Bern, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cioccari et al. Trials  (2018) 19:362 
https://doi.org/10.1186/s13063-018-2714-4
(Continued from previous page)
Discussion: The effect of using echocardiography as a monitoring modality on relevant patient outcomes has not
been established so far. The study at hand may be one of the first trials to provide detailed data on effectiveness and
safety of echocardiography to guide treatment in patients with circulatory shock.
Trial registration: ClinicalTrials.gov, ID: NCT02048566. Registered on January 29, 2014.
Keywords: Circulatory shock, Intensive care unit, Hemodynamic monitoring, Echocardiography,
Background
Hemodynamic management of critically ill patients is a
constant challenge in the intensive care unit (ICU).
Available monitoring parameters to guide hemodynamic
management consist of measurements of pressures
(systemic and pulmonary artery pressures, central venous
pressure) and flow (cardiac output measurements). How-
ever, cardiac filling pressure data have known limitations
and might not accurately represent cardiac preload and
contractility [1]. To date, continuous or sequential record-
ing of cardiac output parameters is limited to pulse con-
tour analysis and indicator-dilution techniques [2]. These
methods allow only an incomplete characterization of the
patient’s cardio-circulatory status and comparisons of dif-
ferent measurements of cardiac function parameters are
reported to trend differently in response to therapy and to
show limited inter-device agreement [3]. Hemodynamic
management of critically ill patients based on these
parameters might, therefore, not be optimal and delay the
stabilization of the patient, leading to worse outcomes and
increased use of resources [4].
Echocardiography is an established tool to evaluate the
causes of hemodynamic instability in ICU patients by the
visualization of cardiac chambers, valves and pericardium
and of cardiac functional abnormalities [5, 6]. Transtho-
racic (TTE) or transesophageal (TEE) echocardiography
can be used as a first-line approach for a quick and
focused examination [7]. However, the training necessary
to reliably perform focused echocardiography is substan-
tial [8, 9] and the method is not readily available for every
intensivist. A repeated echocardiographic assessment
could potentially provide useful additional information
resulting in more rapid resolution of hemodynamic
instability [10]. Monitoring hemodynamics with conven-
tional TTE and TEE is not feasible due to a lack of time
and availability of appropriately trained staff.
A miniaturized monoplane TEE probe that can be left
inserted in the esophagus for up to 3 days has been
recently developed. Qualitative hemodynamic TEE
assessment (hTEE) using the miniaturized probe allows
for almost continuous echocardiographic monitoring of
unstable ICU patients [11], and can provide useful add-
itional information for hemodynamic management when
compared to standard, non-ultrasound-based monitoring
modalities [10]. The feasibility of such qualitative hTEE
by intensivists after a 6-h bedside training has been
demonstrated [12]. However, as of yet, studies assessing
the impact of hemodynamic monitoring by hTEE on
relevant patient outcomes are not available. Given the
associated costs for the hTEE device and the ultrasound
probes and the additional resource requirements for
training and use, the efficacy and efficiency of hTEE
monitoring in comparison to standard monitoring
should be established.
Methods
Hypothesis
The primary study hypothesis is that hemodynamic moni-
toring using hTEE in critically ill patients receiving cardio-
vascular support allows for a shorter time to resolution of
circulatory shock compared to standard ICU monitoring
alone, using a central venous catheter, pulmonary artery
catheter, or conventional TTE and TEE. In this context,
we define time to resolution of shock as the time from
randomization to the time point of resolution of circula-
tory shock (first time point fulfilling the definition mean
arterial pressure (MAP) ≥ 60 mmHg for at least 4 h after
discontinuation of vasopressors and inotropes). The
secondary hypothesis is that hemodynamic assessment at
least every 4 h results in shorter time to resolution of
circulatory shock as compared to standard hemodynamic
assessment (at least once per nursing shift).
Objectives
The primary objective of the study is to assess whether
hemodynamic monitoring using the hTEE technology
shortens time to resolution of shock in ICU patients in
comparison to standard monitoring using a central venous
catheter, pulmonary artery catheter, or conventional
echocardiography. Secondary objectives include whether
hemodynamic assessment at mandated 4-hourly intervals
shortens the time to resolution of shock in comparison to
standard assessment intervals, as well as the safety and
tolerability of the hTEE probe.
Outcomes
The primary study outcome is the time from study inclu-
sion to resolution of circulatory shock (as defined above).
The secondary outcomes include the time to resolution of
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clinical signs of shock (capillary refilling time < 3 s, urine
output > 0.5 mL/kg/h for at least 4 h, blood lactate <
2 mmol/L)), the length of time on organ support (mech-
anical ventilation, renal-replacement therapy), length of
stay (LOS) in the ICU and in hospital, ICU and hospital
mortality, and the use of conventional hemodynamic
monitoring (pulmonary artery catheter, central venous
catheter, conventional echocardiography) and occurrence
of SAE. A detailed description of study outcomes and
adverse events is included in Additional file 1.
Trial design
This is a randomized, open label, 2 × 2 factorial design, con-
trolled clinical trial comparing the effect of hemodynamic
monitoring using the hTEE technology (ImaCor ClariTEE
system IMACOR, New York, NY, USA) or standard
hemodynamic monitoring in a single center. Patients with
circulatory shock, defined as persistent hypotension despite
adequate fluid resuscitation and signs of hypoperfusion or
organ dysfunction (at least one of the following: capillary
refilling time 3 s or longer, urine output < 0.5 mL/kg for at
least 1 h, lactate > 2 mmol/L) are included into the study at
the time of ICU emergency admission. Subjects are
randomized into four groups using a 2 × 2 factorial study
design. The four groups are stratified by method of
hemodynamic monitoring (hTEE vs standard hemodynamic
monitoring) and frequency of hemodynamic assessments
(protocolized maximal interval of 4 h vs standard monitor-
ing intervals with maximal interval of 8 h). Assessed factors
are use of hTEE monitoring vs conventional monitoring
and use of protocolized intervals for hemodynamic assess-
ment vs standard assessment intervals. The Standard
Protocol Items Recommendations for Interventional Tri-
als (SPIRIT) checklist is attached as Additional file 2.
Study setting
The study is performed at the Department of Intensive
Care Medicine of the University Hospital Bern, a 60-bed
ICU in a 960-bed tertiary care center in Switzerland.
hTEE operators
ICU specialists perform the study examinations. All
hTEE operators receive a total of 4 h training in the use
of hTEE by an experienced operator. Training includes
an introduction to the method and a demonstration of
the device use in the context of a presentation, followed
by one-to-one bedside training of all necessary skills to
use the hTEE device for acquiring and interpreting
images in the study context.
Patient eligibility criteria
All ICU patients are screened at the time of ICU admis-
sion for eligibility for the study. All ICU admissions of the
last 24 h are additionally and independently screened to
identify missed study patients each day at 8 a.m. to achieve
adequate patient enrollment. Subjects of 18 years of age or
older who require mechanical ventilation through an
endotracheal, naso-tracheal, or tracheostomy tube with
circulatory shock of any cause are included in the study.
Circulatory shock is defined as follows:
 Systemic mean arterial blood pressure < 60 mmHg
(or < 80 mmHg if the patient has baseline
hypertension) for more than 30 min despite
adequate fluid resuscitation (minimum of 20 mL/kg
of crystalloids) or maintaining the systemic mean
arterial blood pressure ≥ 60 mmHg requires any
dose of vasopressors (norepinephrine, vasopressin)
or inotropes (epinephrine, dobutamine, milrinone,
aminophylline)
 Signs of hypoperfusion or organ dysfunction (at least
one of the following: capillary refilling time 3 s or
longer, urine output < 0.5 mL/kg for at least 1 h,
lactate > 2 mmol/L)
Patient exclusion criteria
Exclusion criteria consist of pathologies of the upper
gastrointestinal tract (unrepaired trachea-esophageal fis-
tula, history of prior esophageal or gastric surgery pre-
cluding the use of TEE, esophageal obstruction, stricture,
varices or diverticulum, esophageal or gastric perforation
or esophageal bleeding, vascular ring, aortic arch anomaly
with or without airway compromise, recent oropharyngeal
surgery) and severe coagulopathy (thrombocyte count less
than 30 × 109/L or INR > 3). Additionally, patients with
cervical spine injury or anomaly, patients after elective
ICU admission after planned surgery and patients with
cardiac assist devices (intra-aortal balloon pump, ventricu-
lar assist devices, extra-corporeal membrane oxygenation)
are not included in the study.
Allocation
The allocation sequence was generated before com-
mencement of the study by ICU research staff using
computer-generated random numbers with randomly
varying block sizes of 4, 8 and 12 [13]. Allocations con-
cealment is ensured using sequentially numbered, identi-
cal, opaque, sealed envelopes. Patients are randomized
and enrolled by the admitting on-call ICU specialist after
reviewing the inclusion and exclusion criteria and after
obtaining confirmation by a physician who is not partici-
pating in study that the interests of the patient are safe-
guarded. Due to logistical reasons (two hTEE devices
available for the study) inclusion of a maximum of two
patients into the groups applying hTEE is possible at the
same time. Randomization and recruitment is interrupted
as soon as a second patient is randomized into a treatment
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group in which hTEE is applied. Randomization and
recruitment is restarted as soon as at least one hTEE
device is available for further patients. Blinding of health
care providers is not feasible which means that all clinical
staff caring for the patients are aware of the allocation
during the study period.
Interventions and study procedures
The subjects are assigned to one of four groups
stratified by method of hemodynamic monitoring
(hTEE vs control hemodynamic monitoring) and fre-
quency of hemodynamic assessments (protocolized
maximal interval of 4 h vs standard monitoring inter-
vals with maximal interval of 8 h) (Table 1):
In patients randomized to echocardiography-guided
hemodynamic management (hTEEPM and hTEESM) the
ImaCor ClariTEE system (IMACOR, New York, NY, USA)
is installed at the time of study inclusion by the ICU
specialist in charge of the patient. The device produces a
single-plane two-dimensional image and has color Doppler
capability. The hTEE probe is a 5.5-mm detachable probe;
due to its small size, it can remain in situ for up to 72 h
and, therefore, allows for reassessment of the patient’s
hemodynamic progress and the effect of selected in-
terventions at any time. Before insertion, the probe is
connected to a dedicated echocardiographic system,
which allows the recording of digital loops and the
performance of basic two-dimensional measurements
of areas and distances. Additional hemodynamic mon-
itoring modalities are restricted to techniques rou-
tinely used at the study center (central venous
catheter, pulmonary artery catheter, and conventional
echocardiography) and can be used at the discretion
of the ICU specialist in charge. After positioning of
the hTEE probe, the following three hTEE standard
views and measurements are acquired and performed:
 transgastric mid-esophageal short-axis view (TG
mid SAX); fractional area change (FAC) of left ven-
tricle (LV)
 Mid-esophageal four-chamber view (ME four-
chamber); ratio of right ventricular (RV) to left
ventricular area (RVEDA/LVEDA ratio)
 Mid-esophageal ascending aortic short-axis view
(ME asc aortic SAX); collapsibility index of superior
vena cava (SVC CI)
Left ventricular areas at end-systole (LVESA) and at
end-diastole (LVEDA) are measured from the TG mid
SAX view, the fractional area change (FAC) of the left
ventricle (LV) is calculated as LVEDA/LVESA and used to
grade left ventricular ejection fraction as normal (FAC >
50%), moderately decreased (FAC 40–50%) or severely de-
creased (FAC < 40%). Similarly, calculation of the RV/LV
ratio is performed by measuring left and right ventricular
areas at end-diastole in the ME four-chamber view. A ra-
tio > 0.6 is used as indicator of right ventricular dysfunc-
tion. The collapsibility of the superior vena cava (SVC) is
rated by calculating the collapsibility index, i.e., the in-
spiratory decrease in SVC diameter. The index is deter-
mined as (maximal diameter on expiration – minimal
diameter on inspiration)/maximal diameter on expiration,
expressed as a percentage [14]. A threshold of > 35% is
used to distinguish between the presence and absence of
hypovolemia. After image acquisition, the ICU specialist
answers the following questions about quantification/inter-
pretation of all hemodynamic monitoring and subsequent
changes in hemodynamic management using a study case
report form (CRF) (Table 2):
In patients randomized to conventional hemodynamic
management (ControlPM and ControlSM) hemodynamic
monitoring is established at the discretion of the ICU spe-
cialist in charge. The use of hTEE is excluded in this
group, whereas the use of conventional TTE or TEE is
Table 1 Study groups
Study group Hemodynamic monitoring Monitoring interval n
hTEE protocolized monitoring
(hTEEPM)
• hTEE-guided hemodynamic management
• Additional hemodynamic monitoring of
choice of the treating physician
• Study inclusion
• Time of occurrence of new organ system deterioration
• At least every 4 h
125
hTEE standard monitoring
(hTEESM)
• hTEE-guided hemodynamic management
• Additional hemodynamic monitoring of
choice of the treating physician
• Study inclusion
• Follow-up measurement time points at the discretion
of the treating physician
• At least every 8 h (standard of care in our ICU)
125
Control protocolized monitoring
(ControlPM)
• Any hemodynamic monitoring of choice
of the treating physician except hTEE
• Study inclusion
• Time of occurrence of new organ system deterioration
• At least every 4 h
125
Control standard monitoring
(ControlSM)
• Any hemodynamic monitoring of choice
of the treating physician except hTEE
• Study inclusion
• Follow-up measurement time points at the discretion
of the treating physician
• At least every 8 h (standard of care in our intensive
care unit (ICU))
125
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permitted. After hemodynamic assessment, the ICU spe-
cialist answers the same questions about quantification/in-
terpretation of all hemodynamic monitoring and
subsequent changes in hemodynamic management as in
groups hTEEPM and hTEESM (Table 2).
Study procedures and measurements in all groups are
performed until the primary outcome (resolution of shock)
occurs or for a maximum of 72 h. Criteria for discontinuing
hTEE monitoring are any occurrence of complications
potentially attributed to the use of hTEE such as oral,
pharyngeal, esophageal, or gastrointestinal bleeding or
injury and cardiac arrhythmias (supraventricular/ventricular
tachycardia, atrioventricular block, asystole) attributed to
the presence of an hTEE probe by the treating physician.
For the control groups (ControlPM, ControlSM) criteria
for discontinuing the allocated intervention have not been
defined as they receive standard intensive care. Adherence
to the study protocol is monitored for each included patient
by daily monitoring of completion of study CRF by the re-
search staff. Concomitant care for all study groups consists
of standard interventions in the context of the routine care
of ICU patients as per the decision of the treating ICU
specialist. The ICU uses a cardiovascular management
protocol to guide hemodynamic stabilization [15]. Com-
monly used monitoring modalities consist of measurement
of arterial and central venous pressure, use of pulmonary
artery catheters with continuous monitoring of cardiac out-
put and mixed venous saturation, and conventional echo-
cardiography. The standard vasopressor is norepinephrine;
standard inotropes are dobutamine, milrinone and epineph-
rine. Pulse-contour analysis modalities are not applied.
Participant timeline
The time schedule of enrollment, interventions and
assessments is outlined in Fig. 1. Recruitment of study
subjects started in March 2014 and is ongoing.
Sample size
Sample size calculation is based on a retrospective analysis
of a sample of 159 patients admitted to our ICU during a
3-month period, which fulfilled the study entry criteria.
Median time to resolution of circulatory shock, defined as
mean systemic blood pressure > 60 mmHg and resolution
of clinical signs of shock (capillary refilling time < 3 s,
urine output > 0.5 mL/kg/h for at least 4 h, blood lactate
< 2 mmol/L), in this sample was 18.5 h (Fig. 1). We used
the Stata command artsurv to calculate the sample size
[16]. We applied the unweighted log-rank test and derived
expected probabilities of hemodynamic stabilization and
loss-to-follow up (i.e., death) over time from the retro-
spective analysis. To identify a clinically relevant reduction
of time to resolution of circulatory shock of 25% (i.e., from
18.5 to 14.0 h) we calculated a required sample size of 458
patients to achieve a power of 80% at a two-sided alpha
level of 0.05 for the main effect (comparison of monitor-
ing with/without hTEE). In order to allow for study drop
out, the inability to consent, or the withdrawal of consent,
we choose a sample size of 125 patients for each of the
four groups or 500 patients in total. Patient recruitment
will be continued until a total of 500 patients with a
complete study follow-up, and in which consent for study
inclusion has been obtained by the patient, are included
into the study.
Data collection methods
In all study patients, hemodynamic parameters, use of
vasopressors/inotropes as continuous intravenous infu-
sions, parameters determined by organ support (mechan-
ical ventilation, renal-replacement therapy) and results of
blood sampling are registered automatically by the
electronic patient data management system (PDMS) as
part of the routine patient data collection. Capillary refill
time (hourly) and ICU resource use (accumulated TISS
points, hourly) and urinary output (2-hourly) are part of
the routine data collection performed by the bedside ICU
nurse; these data are manually entered into the PDMS.
LOS in hospital and hospital mortality are extracted from
the hospital database. Blood lactate levels are measured in
study patients at least every 2 h. A paper-based study CRF
is the primary data collection instrument for the study. All
Table 2 Quantification/interpretation of hemodynamic monitoring and changes in hemodynamic management
Quantification/interpretation of all hemodynamic monitoring Changes in hemodynamic management based on information
acquired by hemodynamic monitoring?
• Systolic LV function: normal – moderately decreased – severely decreased?
• RV dysfunction: present –absent?
• Hypovolemia: present – absent?
• Clinically significant pericardial effusion: present – absent?
• Was the information acquired by hemodynamic monitoring useful to
guide hemodynamic management? Yes – no?
• Is there need for further monitoring? Yes – no?
• No changes
• Additional fluids given
• Start/increase of inotropes (epinephrine, dobutamine, milrinone,
aminophylline)
• Stop/decrease inotropes (epinephrine, dobutamine, milrinone,
aminophylline)
• Start/increase of vasopressors (norepinephrine, vasopressin)
• Stop/decrease of vasopressors (norepinephrine, vasopressin)
• Drainage of pericardial effusion
• Other (to be specified)
RV right ventricular, LV left ventricular
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study data necessary for statistical analysis according to
the SAP are recorded in the CRF. All data requested on
the CRF are recorded during hemodynamic assessment. If
a space on the CRF is left blank because the procedure
was not done or the question was not asked, “N/D” is
written instead. If an item is not applicable to the individ-
ual case, “N/A” is written. All corrections must be initialed
and dated. All hTEE echocardiography loops are recorded
and saved for independent and blinded off-line review.
Data management
Data are entered into a web-based electronic CRF. Study
subjects are assigned an individual identifying study code
on all data documents, which does not contain identify-
ing information. The investigators keep a separate docu-
mentation that links the study code to subjects’
identifying information locked in a separate location and
restrict access to this document to research staff. CRF
and electronic data are archived for 10 years.
Statistical methods
Continuous baseline and procedural variables will be
displayed as mean (standard deviation) for normally and
median (quartiles) for non-normally distributed data,
categorical variables as number (percentage). The pri-
mary analysis will be an intention-to-treat (ITT) analysis,
i.e., all patients will be analyzed as randomized. We will
first test the primary hypothesis, the difference in time
to hemodynamic stabilization between the hTEE and
standard group. Second, we will evaluate the difference
between the protocoled and standard monitoring. Differ-
ences in the primary outcome will be assessed using the
Fine-Gray competing risk model accounting for the
competing risk of death [17]. The model that compares
the method of monitoring (hTEE vs standard) will be
adjusted for the frequency of monitoring (protocolizedvs
standard), the model that compares the frequency of
monitoring for the method of monitoring. We will also
test for an interaction between the method (hTEE vs
Fig. 1 Participant timeline
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standard) and frequency of hemodynamic monitoring
(protocolized vs standard) in order to assess if effects are
different depending on the method and frequency of
monitoring. We will enter an interaction term in the
model described above. If there is significant interaction,
we will present effects separately in subgroups.
The secondary outcome, time to death, will be evaluated
using Cox proportional-hazards regression. Other second-
ary time-to-event outcomes will be analyzed using com-
peting risk models as described above. Binary outcomes
will be analyzed using logistic regression, continuous score
data using linear regression. We will also perform a
secondary per-protocol analysis excluding patients that
did not receive the allocated interventions or had major
protocol violations. Statistical analyses will be described in
more detail in a statistical analysis plan (SAP).
Data monitoring
The trial is externally monitored (Clinical Trials Unit,
Bern, Switzerland) in accordance with Good Clinical
Practice (GCP) standards.
Monitoring harm
Occurrence of adverse events due to prolonged hemodynamic
impairment and treatment with vasopressors/inotropes
is registered, including ventricular tachycardia, ven-
tricular fibrillation, atrial fibrillation, myocardial infarc-
tion as defined in [18], skin necrosis, stroke, secondary
bowel or limb ischemia, secondary infections (cathe-
ter-related infections, ventilator-associated pneumonia
VAP, new onset of sepsis) and gastrointestinal bleeding
complications. Additionally, any occurrence of complica-
tions potentially attributed to the use of hTEE such as oral,
pharyngeal, esophageal, or gastrointestinal bleeding or in-
jury, cardiac arrhythmias occurring while hTEE probe is in
place (supraventricular/ventricular tachycardia, atrioven-
tricular block and asystole) and need for additional sedation
and/or muscle relaxants for hTEE probe placement and
hTEE assessment is recorded. The study includes critically
ill patients with circulatory shock. Depending on the rea-
sons for hemodynamic impairment and comorbidities a
mortality rate of up to 50% has to be expected [19]. In ac-
cordance with current guidelines, serious adverse events
(SAE) and serious adverse device effect (anticipated or un-
anticipated) will be thoroughly investigated to determine
causality and reported to the appropriate authorities
(Kantonale Ethikkommission Bern) if a relation be-
tween SAE and study procedures is considered unlikely,
likely, or certain, or in the event of death of the patient.
No SAE report is made if a connection between SAE
and study procedures can be excluded. Subjects
experiencing any trial-related adverse events will re-
ceive the best possible care, including follow-up visits
as clinically indicated.
Confidentiality
Information about study subjects is kept confidential. A
signed subject authorization is part of the informed
consent documents, informing the subject what protected
health information (PHI) is collected from subjects in this
study, who will have access to the information and the
rights of a research subject to revoke their authorization
for use of their PHI. All data are entered into a dedicated
study data management system. Study subjects are
assigned an individual identifying study code on all data
documents (e.g., completed questionnaire) which does not
contain identifying information. The investigators keep a
separate documentation that links the study code to sub-
jects’ identifying information in a separate location.
Discussion
The targeted patient population fulfills the definition of cir-
culatory shock, representing the most severely ill patients
with plausibly the highest possible chance to show a differ-
ence between the intervention arms. Echocardiography has
proven a useful tool to identify reversible causes of shock
and to monitor left and right ventricular function [20].
However, despite several class 1 recommendations for its
use in the ICU, the effect of echocardiography as a moni-
toring modality on relevant patient outcomes has not been
studied in large randomized trials so far. The study at hand
aims at establishing the effect of frequent hemodynamic
TEE monitoring using a miniaturized probe that allows
minimizing invasiveness of TEE examinations. The study
may be one of the first trials to bridge the gap between
evidence and clinical practice and to provide detailed data
on efficacy and safety of echocardiography to guide treat-
ment in patients with circulatory shock.
Strengths and limitations
To our knowledge, this is the largest randomized controlled
trial of the effect of hTEE-monitoring in critically ill
patients with circulatory shock. The primary outcome is
objective and verifiable, and the statistical analysis adjusts
for frequency and method of monitoring, including testing
for interaction, in order to assess if any difference in
outcome depends on the method or on the frequency of
monitoring. The feasibility of hTEE monitoring has been
previously established and the technology has shown to
provide additional valid information for the management of
critically ill patients. Our study has some limitations. First,
patients and health care providers are not blinded. How-
ever, due to the nature of the intervention, blinding is not
feasible in this setting. Second, hemodynamic management
is not standardized, but remains at the discretion of the
treating physician. This is likely to reflect clinical practice
and avoids introducing a potential confounder (such as a
treatment protocol). Third, the single-center design may
limit external validity. However, our unit is a tertiary ICU
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in a large university hospital and, therefore, is likely to re-
flect current best practice in the management of critically ill
patients with shock.
Trial status
Patient recruitment has started in May 2014, recruitment
will likely be completed by December 2017. Protocol V2
01.12.2013.
Additional files
Additional file 1: Definitions and measurement of outcome parameters
and serious adverse events. (DOCX 44 kb)
Additional file 2: Standard Protocol Items: Recommendations for
Interventional Trial (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 168 kb)
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safeguarded and that all inclusion criteria and no exclusion criteria are present.
Thereafter, deferred consent involving study inclusion according to the stated
criteria in this protocol, followed by the request for a representative’s (deferred
proxy consent, within 72 h) and patient’s informed consent (deferred subject
consent, as soon as patient’s conditions allows) in a later phase, is used. All
subjects for this study and their designed representatives receive a consent
form describing this study and providing sufficient information for subjects to
make an informed decision about their participation in this study. The consent
form must be signed by the subject or legally acceptable surrogate, and the
investigator-designated research professional obtaining the consent. In cases
where the patient’s representative’s consent to the study and the patient’s
consent cannot be obtained due to the patient’s condition (death, neurological
compromise) after provisional study inclusion by proxy consent, the data are
used for further analysis. In cases where it is not possible to contact relatives, or
if no relatives exist and the patient’s consent cannot be obtained due to the
patient’s condition (death, neurological compromise) after provisional study
inclusion by deferred consent, the data are used for further analysis. In the
event that a study patient dies before being able to come to an informed
decision on study participation and no relatives are available for deferred
proxy consent, the collected data are used for analysis [21, 22]. If the patient or
relatives deny consent for study inclusion or if the patient or relatives withdraw
consent at any time after provisional study inclusion by deferred consent, data
are not used for further analysis.
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